Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1959 1
1961 1
1962 2
1963 7
1964 3
1965 3
1967 4
1968 5
1969 9
1970 3
1971 7
1972 15
1973 13
1974 19
1975 32
1976 19
1977 20
1978 40
1979 31
1980 27
1981 30
1982 30
1983 36
1984 36
1985 33
1986 51
1987 45
1988 50
1989 55
1990 28
1991 38
1992 28
1993 39
1994 35
1995 46
1996 45
1997 49
1998 60
1999 57
2000 59
2001 69
2002 56
2003 61
2004 69
2005 74
2006 70
2007 82
2008 74
2009 57
2010 96
2011 128
2012 118
2013 134
2014 135
2015 140
2016 115
2017 130
2018 121
2019 122
2020 146
2021 181
2022 177
2023 150
2024 49

Text availability

Article attribute

Article type

Publication date

Search Results

3,356 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Makker V, et al. Among authors: fujiwara k. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045221 Clinical Trial.
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. Among authors: fujiwara k. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE, Okamoto A, Moore K, Kridelka F, McNeish I, Reuss A, Votan B, du Bois A, Mahner S, Ray-Coquard I, Kohn EC, Berek JS, Tan DSP, Colombo N, Zang R, Concin N, O'Donnell D, Rauh-Hain A, Herrington CS, Marth C, Poveda A, Fujiwara K, Stuart GCE, Oza AM, Bookman MA; participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research. Vergote I, et al. Among authors: fujiwara k. Lancet Oncol. 2022 Aug;23(8):e374-e384. doi: 10.1016/S1470-2045(22)00139-5. Lancet Oncol. 2022. PMID: 35901833 Free PMC article. Review.
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Provencher D, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Drochýtek V, Barlin JN, Van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Moore K, Marme F, Westin SN, McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS. Monk BJ, et al. Among authors: fujiwara k. J Clin Oncol. 2022 Dec 1;40(34):3952-3964. doi: 10.1200/JCO.22.01003. Epub 2022 Jun 6. J Clin Oncol. 2022. PMID: 35658487 Free PMC article. Clinical Trial.
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Harter P, Mouret-Reynier MA, Pignata S, Cropet C, González-Martín A, Bogner G, Fujiwara K, Vergote I, Colombo N, Nøttrup TJ, Floquet A, El-Balat A, Scambia G, Guerra Alia EM, Fabbro M, Schmalfeldt B, Hardy-Bessard AC, Runnebaum I, Pujade-Lauraine E, Ray-Coquard I. Harter P, et al. Among authors: fujiwara k. Gynecol Oncol. 2022 Feb;164(2):254-264. doi: 10.1016/j.ygyno.2021.12.016. Epub 2021 Dec 22. Gynecol Oncol. 2022. PMID: 34952708 Free article. Clinical Trial.
An ERK5-NRF2 Axis Mediates Senescence-Associated Stemness and Atherosclerosis.
Abe JI, Imanishi M, Li S, Zhang A, Ko KA, Samanthapudi VSK, Lee LL, Bojorges AP, Gi YJ, Hobbs BP, Deswal A, Herrmann J, Lin SH, Chini EN, Shen YH, Schadler KL, Nguyen TH, Gupte AA, Reyes-Gibby C, Yeung SJ, Abe RJ, Olmsted-Davis EA, Krishnan S, Dantzer R, Palaskas NL, Cooke JP, Pownall HJ, Yoshimoto M, Fujiwara K, Hamilton DJ, Burks JK, Wang G, Le NT, Kotla S. Abe JI, et al. Among authors: fujiwara k. Circ Res. 2023 Jun 23;133(1):25-44. doi: 10.1161/CIRCRESAHA.122.322017. Epub 2023 Jun 2. Circ Res. 2023. PMID: 37264926 Free article.
Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775.
Yonemori K, Yunokawa M, Ushijima K, Sakata J, Shikama A, Minobe S, Usami T, Enomoto T, Takehara K, Hasegawa K, Yamagami W, Yamamoto K, Han S, Dutta L, Orlowski R, Miura T, Makker V, Fujiwara K. Yonemori K, et al. Among authors: fujiwara k. Cancer Sci. 2022 Oct;113(10):3489-3497. doi: 10.1111/cas.15436. Epub 2022 Jul 26. Cancer Sci. 2022. PMID: 35612971 Free PMC article. Clinical Trial.
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
Nishio S, Yonemori K, Usami T, Minobe S, Yunokawa M, Iwata T, Okamoto A, Aoki Y, Itamochi H, Takekuma M, Harano K, Yamamoto K, Maruko T, Ugai H, Tekin C, Colombo N, Fujiwara K, Hasegawa K, Ushijima K. Nishio S, et al. Among authors: fujiwara k. Cancer Sci. 2022 Nov;113(11):3877-3887. doi: 10.1111/cas.15479. Epub 2022 Sep 15. Cancer Sci. 2022. PMID: 35792064 Free PMC article. Clinical Trial.
Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study.
Fotopoulou C, Khan T, Bracinik J, Glasbey J, Abu-Rustum N, Chiva L, Fagotti A, Fujiwara K, Ghebre R, Gutelkin M, Konney TO, Ng J, Pareja R, Kottayasamy Seenivasagam R, Sehouli J, Surappa STS, Bhangu A, Leung E, Sundar S; CovidSurg Gynecological Cancer Collaborators. Fotopoulou C, et al. Among authors: fujiwara k. Am J Obstet Gynecol. 2022 Nov;227(5):735.e1-735.e25. doi: 10.1016/j.ajog.2022.06.052. Epub 2022 Jun 30. Am J Obstet Gynecol. 2022. PMID: 35779589 Free PMC article.
3,356 results